ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators with a highly differentiated & diversified portfolio of first-in-class therapeutic antibodies in cancers and auto-immunity. ImCheck is a spin-off from Marseille’s Institut Paoli-Calmettes (IPC), one of the leading cancer centers in Europe and developing intellectual property licensed from Inserm Transfert and SATT-SE. The company was founded in 2015 around Daniel Olive (Professor of immunology at Aix-Marseille University (AMU) and IPC), a pioneer in innate immunity & co-signaling molecules and Head of the immune monitoring program for early stage clinical trials in oncology at IPC. With a precision medicine-based translational approach and several established academic collaborations, ImCheck is uniquely positioned to develop the right therapy for the right patient. To-date, ImCheck is developing two first-in-class immunomodulator antibodies and is advancing several discovery programs on undisclosed targets, who play a defined immune-modulating role in both innate and adaptive immunity.

Deja una respuesta